Expression and significance of TSHR, TTF-1 and Pax-8 in papillary thyroid carcinoma
Liu Lin1,2, Wang Lizhe2, Zhang Yongqing3, Li Rujiang4, Zhuang Baoxiang5
1 Department of Endocrinology, Weifang People′s Hospital, Weifang 261041, China;
2 Department of Internal Medicine, Weifang Medical University, Weifang 261053, China;
3 Department of Thyroid Surgery, Weifang People′s Hospital, Weifang 261041, China;
4 Department of Histoembryology, Weifang Medical University, Weifang 261053, China;
5 Department of Morphology, Weifang Medical University, Weifang 261053, China
Abstract：Objective To investigate the expression and significance of thyrotropic-stimulating hormore receptor (TSHR), thyroid transcription factor-1 (TTF-1), paired box gene-8 (Pax-8) in papillary thyroid carcinoma (PTC), Hashimoto′s disease (HT) with PTC, nodular goiter (NG) and normal thyroid tissues. Methods From September 2018 to June 2019, thyroid tissues confirmed in the Endocrine Department of our hospital and operated in the Thyroid Surgery were collected, including 16 cases of simple PTC, 24 cases of HT combined with PTC, 32 cases of nodular goiter and 40 cases of normal thyroid tissues adjacent to the carcinoma. The thyroid tissues obtained during the operation were treated with dehydration, transparency and embedding. Immunohistochemical staining of TSHR, TTF-1 and Pax-8 was performed, and the staining results were observed under the microscope.The Chi-square test was used to compare the intergroup rates, and when the difference was statistically significant, Chisquare partition was used to make pairwise comparison. Results 1) There were significant difference about the strong positive expression of TSHR and TTF-1 among four groups of thyroid tissue (P＜0.001,P=0.004), while no significant difference in the strong expression of Pax-8 were found among four groups of thyroid tissue (P=0.642). 2) After adjusting the statistical examination level α′=0.008, pairwise comparison showed that the strong positive expression of TSHR in PTC group was lower than that in NG and normal thyroid tissue(P＜0.001, P=0.002);the strong positive expression of TSHR in HT combined with PTC group was lower than that in NG (P=0.001); while the strong positive expression of TTF-1 in HT combined with PTC group was lower than that in NG (P=0.002).However,there was no significant difference of the strong positive expression of TSHR, TTF-1 in other groups respectively (P>0.008). 3)The positive expression of TSHR,TTF-1 were not related to age, tumor diameter and lymph node metastasis. However, the positive expression of Pax-8 inpatients with lymph node metastasis was lower than that without lymph node metastasis (P=0.030), and the expression of Pax-8 was not related to gender, age, and tumor diameter. Conclusion The strong positive expression of TSHR and TTF-1 in PTC group was lower than that in NG and paracancerous normal thyroid tissues. There was no difference in the expression of Pax8 in different types of thyroid tissues. The lower expression of Pax-8 in PTC tissues might result in lymph node metastasis.
柳林，王丽哲，张永庆，李如江，庄宝祥. 促甲状腺激素受体与TTF-1、Pax-8在甲状腺乳头状癌中的表达及意义[J]. 中国医院统计, 2020, 27(4): 322-325.
Liu Lin, Wang Lizhe, Zhang Yongqing, Li Rujiang, Zhuang Baoxiang . Expression and significance of TSHR, TTF-1 and Pax-8 in papillary thyroid carcinoma. journal1, 2020, 27(4): 322-325.
［1］LI G J, KONG Q L.LncRNA LINC00460 promotes the papillary thyroid cancer progression by regulating the LINC00460/miR-485-5p/Raf1axis［J］. Biological Research.2019，52:61-73. DOI:10.1186/s40659-019-0269-9.
［2］DUPAIN C，ALI H M，MOUHOUB T A，et al.Induction of TTF-1 or PAX-8 expression on proliferation and tumorigenicity in thyroid carcinomas［J］.International Journal of Oncology ，2016，49(3): 1248-1258.
［3］ZENG R，ZHAO M，NIU H，et al.Relationship between Hashimoto’s thyroiditis and papillary thyroid carcinoma in children and adolescents［J］.Eur Rev Med Pharmacol Sci，2018，22 (22): 7778-7787.
［4］吴毅.《甲状腺结节和分化型甲状腺癌临床诊疗指南》热点解读［J］.中华内分泌外科杂志，2012，6(1)：1-2.
［5］PACINIF.Anaplastic thyroidcarcinomaa retrospective clinical and immunohistochemical study［J］.Oncol Rep,1994,1(5):921-925.
［6］RIEDEL C,LEVY O,CARRASCO N.Posttranscriptional regulation of the sodium/iodide symporter by thyrotropin［J］.Biological Chemistry,2001,276(24): 2145-21463.
［7］BIONDI B, COOPER D S. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer［J］. Thyroid, 2010, 20(2):135-146.
［8］戴亚丽,叶静,张帆,等.乳头状甲状腺癌抑癌基因 TSHR、P16 和 RAS 启动子甲基化研究［J］.中华内分泌代谢杂志,2010,26(5):381-384.
［9］RYDZEWSKA M,GORALCZYK A,GOSCIK J，et al.Analysis of chosen polymorphisms rs2476601 a/G-PTPN22, rs1990760 C/T-IFIH1, rs179247 a/G-TSHR in pathogenesis of autoimmune thyroid diseases in children［J］.Autoimmunity,2018，51(4):183-190.
［10］KOYAMA J,HORIIKE A,YOSHIZAWA T,etal.Correlation between thyroid transcription factor1 expression, immunerelated thyroid dysfunction, and efficacy of antiprogrammed cell death protein1 treatment in nonsmall cell lung cancer［J］.Origina Article.2019 ,11(5):1919-1928.
［11］FENTON CL,PATEL A,BURCH HB,et al. Nuclear localization of thyroid transcription factor1 correlates with serum thyrotropin activity and may be increased in differentiated thyroid carcinomas with aggressive clinical course［J］.Ann Clin Lab Sci,2001,31(3):245-252.
［12］PELOSI G, FRAGGETTA F, PASINI F, et al.Immunoreactivity of thyroid transcription factor1 in stage I nonsmall cell carcinomas of the lung［J］.The American Journal of Surgical Pathology, 2001,25(3):363-372.
［13］LOPEZCAMPISTROUS A, ADEWUYI E E, BENESCH M G K，et al. PDGFRα regulates follicular cell differentiation driving treatment resistance and disease recurrence in papillary thyroid cancer［J］. EBioMedicine，2016，12:87-98.DOI：10.1016/j.ebiom.2016.09.007.
［14］OZCAN A，SHEN S S，HAMIITON C，et al.Pax8 expression in nonneoplastic tissues，primary tumors，and metastatic tumors：a comprehensive immunohistochemical study［J］.Mod Pathol，2011，24（3）：751-764.
